Table 5.
MACE
| MACE | Placebo | Canakinumab | p Value | |
|---|---|---|---|---|
| Group | ||||
| All | ||||
| N | 94 | 95 | ||
| Yes | 7 (7) | 10 (11) | 0.612 | |
| No | 87 (93) | 85 (89) | ||
| Type 2 diabetes mellitus | ||||
| N | 81 | 81 | ||
| Yes | 6 (7) | 9 (11) | 0.589 | |
| No | 75 (93) | 72 (89) | ||
| Impaired glucose tolerance | ||||
| N | 13 | 14 | ||
| Yes | 1 (8) | 1 (7) | 1.000 | |
| No | 12 (92) | 13 (93) | ||
Values are n (%) unless otherwise indicated.
MACE = major adverse cardiac events.